Opendata, web and dolomites

ChemRAS SIGNED

Chemical probing of transcriptional RAS effectors

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ChemRAS project word cloud

Explore the words cloud of the ChemRAS project. It provides you a very rough idea of what is the project "ChemRAS" about.

molecular    multiple    clinic    regulation    fail    networks    prone    attempts    models    austrian    understand    disruption    me    dependent    perturbations    active    hyperactive    laboratory    disease    winter    regulatory    transduction    modulation    hence    attractive    targeted    throughput    point    deadly    coupled    reporters    protein    pharmacologic    facile    transcriptionally    resistances    aggressive    readout    amenable    degradation    remodeling    phenotypic    critical    elicited    signaling    pancreatic    academy    building    oncogenes    medicine    treatment    acute    avenues    genetic    mutant    resistance    innovative    kras    cemm    sciences    cancers    transcription    therapeutic    urgent    dependencies    center    computational    exemplified    chromatin    inhibitors    experimental    therapies    cellular    molecules    chemical    confluence    pipelines    underpinning    block    oncogenic    imposed    devise    mechanism    engineering    clinical    cancer    emergence    usually    screens    ras    transcriptional    interface    action    drug    nodes    microscopy    translated    background    regulators    signal    tumors    interfere    gene    unfortunately   

Project "ChemRAS" data sheet

The following table provides information about the project.

Coordinator
CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH 

Organization address
address: LAZARETTGASSE 14 AKH BT 25.3
city: WIEN
postcode: 1090
website: http://www.oeaw.ac.at/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Total cost 178˙156 €
 EC max contribution 178˙156 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-02-15   to  2021-02-14

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH AT (WIEN) coordinator 178˙156.00

Map

 Project objective

Targeted therapies have been widely used in tumors driven by RAS oncogenes. Unfortunately, no effective RAS inhibitors have been translated to the clinic, and attempts to block other signaling nodes usually fail due to the emergence of drug resistance. Chromatin dependent signal transduction and transcription are a point of confluence of multiple signaling networks elicited by hyperactive RAS. Hence, pharmacologic disruption of gene-regulatory dependencies imposed by mutant RAS represents an attractive therapeutic interface less prone to the emergence of resistances. The urgent clinical need of RAS-related therapies is well exemplified by pancreatic cancer, one of the most aggressive and deadly cancers, which will be the disease background of my studies. Using the innovative approach of targeted protein degradation, I want to characterize and understand the consequences of acute mutant KRAS degradation on chromatin remodeling and transcription. Further engineering the models of acute KRAS degradation will enable to devise cellular reporters of KRAS-dependent chromatin regulation amenable to high-throughput phenotypic drug and genetic screens. Coupled to a facile readout via high-throughput microscopy, these screens will allow me to identify molecules and genetic perturbations that interfere with KRAS-dependent, transcriptionally active chromatin. Lead molecules will be characterized for the underpinning mechanism of action and assessed for therapeutic potential. Building on already existing experimental and computational pipelines in the Winter laboratory at CeMM-Research Center for Molecular Medicine of the Austrian Academy of Sciences, this project will increase the understanding of transcriptional control elicited by oncogenic KRAS and could open new avenues for the treatment of RAS-driven tumors based on chemical modulation of critical chromatin and transcription regulators.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CHEMRAS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CHEMRAS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

NeoPur (2019)

New treatments and novel diagnostic tests for neonatal seizures based on purinergic signaling.

Read More  

FOCUSIS (2020)

Focal volume Control Using Structured Illumination Sources

Read More